TELA Bio holders approve 1-for-5 to 1-for-15 reverse split; no split planned after Nasdaq compliance regained

TELA Bio, Inc.

Special Meeting held October 8, 2026; 45,143,410 common shares outstanding as of the September 8, 2026 record date.
Proposal 1 approved: 30,515,571 votes for, 80,512 against, 1,737,011 abstentions, 0 broker non-votes.
Amendment would combine shares at a ratio of not less than one-for-five and not more than one-for-fifteen, exact ratio set by the Board in its sole discretion.
Proposal 2 (adjournment if needed) approved: 30,757,679 for, 123,860 against, 1,451,555 abstentions.
October 5, 2026 Nasdaq letter stated the company regained compliance with Listing Rule 5450(a)(1) minimum bid price; TELA Bio does not intend to effect the reverse split at this time.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.